The use of the PSA as a prostate cancer screening tool has been a controversial issue for many years. Within the last year the issue has again come to the forefront of the public awareness, especially because of the recent move of the U.S Preventative Task Force to discourage using the PSA as a screening [...]
Bavarian Nordic A/S (BAVA) announced on November 15, that its subsidiary, BN ImmunoTherapeutics has started the pivotal Phase 3 trial of PROSTVAC® for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial is being conducted under a Special Protocol Assessment agreement with the FDA. Notice this trial has the same criteria as [...]
According to a an article published in the January 2012 issue of Cancer Prevention Research, estrogen may play a role in Melanoma recurrences! The article described a large cohort study of women who were put on an anti-estrogen therapy. The study concluded that those women on the anti-estrogen therapy had a lower risk of melanoma. [...]
Neulasta (Pegfilgrastim) is used to reduce the chance of infection in people who have certain cancers and are also receiving chemotherapy medications, including taxotere for men being treated for advanced prostate cancer. Chemotherapy is designed to kill fast growing cells. However, it can’t tell the difference between cancer cells and fast-growing healthy cells, including red [...]
We are about to finally get a more formal presentation of the great news we have all been waiting to hear. Medivation Inc. and Astellas Pharma Inc. announced that data from their Phase 3 AFFIRM trial, evaluating MDV3100 in men with advanced prostate cancer, will be highlighted in a late-breaking oral presentation at the upcoming [...]